How is it treated
The majority of cases require no treatment because the infection will go away on its own. When an individual is showing acute infection palliative care with avoidance of alcohol and certain drugs like Tylenol should be adhered to. Chronic suffers may still live a long and active life under the care and supervision of a provider. In some cases chronic hepatitis B may lead to severe liver damage, making it necessary for a liver transplant.
How is it transmitted
Engerix-B by GlaxoSmithKline. In 1989, the FDA approved the first Hep B vaccine Engerix-B by GlaxoSmithKline (Blake, D., 1989). In 1990, the CDC's Advisory committee on Immunization Practices (ACIP) recommended that the Engerix-B by GlaxoSmithKline be administered to newborns. From 1990-2000, Engerix-B contained the full compliment of the mercury derivative thimerosal (25 mcg neurotoxin). From 2000-2007 the multi-dose vials of Engerix-B had trace elements of thimerosal until 2007 when the FDA approved a free formulation (FDA, 2007). The removal of thimerosal from this vaccine was initiated by a joint statement from family physicians, pediatricians, federal health officials, and vaccine manufacturers in 1999 (AAFP, AAP, ACIP, PHS, 2000).
Comvax by Merck. In 1996, the FDA approved this vaccine, which contains Haemophilus b Conjugate Vaccine & Hepatitis B Vaccine (Recombinant) (FDA, 1996).
Recombivax HB by Merck. In 1999, the FDA approved this vaccine which has always been thimerosal free (FDA, 1999).
Twinrix by GlaxoSmithKline. In 2001, the FDA approved this vaccine, which is a combination vaccine containing Hepatitis A & Hepatitis B (Recombinant) (FDA, 2001).
How is the vaccine made?
Engerix-B is a killed virus that was cultured in genetically engineered Saccharomyces cerevisiae (yeast) cells. The total product contains no more than 5% yeast protein. Other ingredients include aluminum hydroxide (0.25mg - 0.5mg neurotoxin), sodium chloride (9mg/mL), disodium phosphate dihydrate (0.98 mg/mL), sodium dihydrogen phosphate dihydrate (0.71 mg/mL), and natural rubber latex.
Comvax is a combination haemophilus B (HIB) conjugate and hepatitis B vaccine. The Hep B portion
is a killed virus that was cultured in genetically engineered Saccharomyces cerevisiae (yeast) cells on a complex fermentation medium which consists of an extract of yeast, soy peptone, dextrose, amino acids and mineral salts. The HIB portion is a killed virus that was cultured in a complex fermentation media, which also contains yeast. The total product contains no more than 1% yeast protein. Other ingredients include aluminum hydroxide (225 mcg neurotoxin), sodium borate (25 mcg), sodium chloride (0.9%), formaldehyde (0.0004%).
Recombivax HB is a killed virus that was cultured in genetically engineered Saccharomyces cerevisiae (yeast) cells. The total product contains no more than 1% yeast protein. Other ingredients include amorphous aluminum hydroxyphosphate sulfate or aluminum hydroxide (0.5 mg neurotoxin), and formaldehyde (<15 mcg/mL).
Twinrix is a combination hepatitis A & Engerix-B vaccine. The Hep A killed virus is propagated in MRC-5 human diploid cells, which is also known as aborted fetal tissue. Other ingredients include aluminum hydroxide (0.45 mg neurotoxin), amino acids, sodium chloride, polysorbate 20, MRC-5 cellular protein (2.5 mcg aborted fetal tissue), neomycin sulfate (20 ng antibiotic), and yeast (5%).
Admitted Adverse Events From The Mainstream Medical Community
According to the U.S. Department of Health and Human Services (HRSA), the hepatitis B vaccine(s) can cause;
Anaphylaxix, or anaphylactic shock, any acute complication or sequela (including death) of an illness, disability, injury, or condition referred to above which illness, disability, injury, or condition arose within the time period prescribed (HRSA, n.d.).
Upper respiratory tract illnesses, lymphadenopathy, somnolence, hypotension, abdominal pain, vomiting, urticaria, arthralgia, myalgia, influenza-like symptoms, malaise, herpes zoster, meningitis, thrombocytopenia, anaphylactoid reaction, arthralgia/arthritis, encephalitis, multiple sclerosis, neuritis, hypoesthesia, paresthesia, Guillain-Barre’ syndrome, Bell’s palsy, optic neuritis, paralysis, paresis, seizures, transverse myelitis. Tinnitus, vasculitis, asthma, dyspepsia, eczema, Stevens-Johnson syndrome, abnormal liver function tests.
Vaccines have not been evaluated for its carcinogenic or mutagenic potential, or is potential to impair fertility.
Research On Hepatitis B Adverse Events
Vaccine Ingredient: Formaldehyde
Formaldehyde has been classified as a known human carcinogen (cancer causing substance) by the International Agency for Research on Cancer and as a probable human carcinogen by the U.S. Environmental Protection Agency. Research studies of workers exposed to formaldehyde have suggested an association between formaldehyde exposure and several cancers, including nasopharyngeal cancer and leukemia (National Cancer Institute, 2011).
Vaccine Ingredient: Aluminum Hydroxide
Some experts believe it plays a role in leading to the formation of Alzheimer-like neurofibrillary tangles. Blaylock et al suggest that the heterogeneous symptoms of autism spectrum disorders have a connection with dysregulation of glutamatergic neurotransmission in the brain along with enhancement of excitatory receptor function by proinflammatory immune cytokines as the underlying pathophysiological process (Bernardo, J., 2012).
The popular over-the-counter drug acetaminophen is a potent oxidant. It depletes GSH (Glutathione) from the cells of the liver, and by so doing renders the liver more vulnerable to toxic damage (Kidd, P., 1997).
Aluminum adjuvants are also associated with "autoimmune conditions in humans", and "serious immunological disorders"(Tomljenovic et al., 2012; Tomljenovic et al., 2011). Other studies show that aluminum-containing vaccines are causal in autism spectrum disorders (Tomljenovic et al., 2011). Further, aluminum hydroxide-containing vaccines;
...shows both long-term persistence of aluminum hydroxide and an ongoing local immune reaction, and is detected in patients with systemic symptoms which appeared subsequently to vaccination (Gherardi et al., 2001).
Vaccine Ingredient: Latex
If a person reports a severe (anaphylactic) allergy to latex, vaccines supplied in vials or syringes that contain natural rubber should not be administered unless the benefit of vaccination outweighs the risk for a potential allergic reaction ( ACIP, 2012).
Vaccine Ingredient: Saccharomyces Cerevisiae (Yeast)
Hepatitis B Ingredient MRC-5 human diploid cells, which is also known as aborted fetal tissue
Dr. Helen Ratajczak, senior scientist formerly with Boehringer-Ingelheim suggests that the human DNA in vaccines cause the body to have an autoimmune event attacking the brain, leading to inflammation creating autistic symptoms (Ratajczak, H., 2011).
Vaccine Ingredient: Antibiotics
Vaccine Adverse Event Reporting System (VAERS)
59,215 events reported from the vaccine (HEP B or HBHEPB) from 1989 to 2013. 36.87% were children under the age of 6 (MedAlerts, 2013).
1,359 Life Threatening 48.86% under the age of 6
18,931 ER Visit 44.66% under the age of 6
4,762 Hospitalized 44.64% under the age of 6
167 Extended Hospital Stay 28.75% under the age of 6
800 Disabled 25.38% under the age of 6
935 Died 86.31% under the age of 3
The current practice of administration of vaccine with HBIG at birth to babies born of HBsAg-positive mothers is not effective in preventing occult HBV infection in babies, which may be up to 40%. Because the most important risk factors for mother-to-baby transmission of HBV infection are the replicative status and high HBV DNA levels in mothers; it will be worthwhile investigating the role of antivirals and HBIG administration during pregnancy to prevent mother-to-child transmission of HBV infection (Pande et al., 2013).
Vaccine Affects In Other Countries
Due to believed reports of neurological and autoimmune pathology following the Hepatitis B vaccination the French government ended their recommendation of the vaccine to adolescents (Akehurst, C., 1998).
Risk Verses Benefit
Independent analysis of raw computer data generated by the government-operated Vaccine Adverse Event Reporting System (VAERS) confirms that in 1996, there were 872 serious adverse events reported to VAERS in children under 14 years of age who had been injected with hepatitis B vaccine. The children were either taken to a hospital emergency room, had life threatening health problems, were hospitalized or were left disabled following vaccination. 214 of the children had received hepatitis B vaccine alone and the rest had received hepatitis B vaccine in combination with other vaccines. 48 children were reported to have died after they were injected with hepatitis B vaccine in 1996 and 13 of them had received hepatitis B vaccine only before their deaths. By contrast, in 1996 only 276 cases of hepatitis B disease were reported in children under age 14 (NVIC, 1999).
What Professionals Are Saying
We have come to believe the hepatitis B vaccine is an assault on a newborns developing neurological and immune system. Vaccines are supposed to be making us healthier; however, in twenty-five years of nursing I have never seen so many damaged, sick kids. Something very, very wrong is happening to our children. The census of ill children seen in our health rooms each day has increased by 300% in only four years. It had remained relatively constant in all the years before (White, P., 1999).
If you have anything you would like to add please comment and leave your raw data. Thank you.
This is resource material and should be used for informational purposes only. I will be updating this article as new developments surface surrounding the vaccine and disease.
I will not tolerate abusive and vulgar language in the comment section. In my private life I do not conduct conversation in that manner and will not allow it here. I've been debating this topic for many years with individuals that do not share my views and I welcome them to this table. The conversations I have had with the opposing side actually strengthened my argument. I was forced to read and go to places my imagination wasn't capable of seeing. I find the banter an asset and I hope it continues here. But it must be polite, or your comments will be deleted. Ad hominem attacks are strictly forbidden.
ACIP. (2012). Latex in vaccine packaging. CDC. Retrieved from http://search.yahoo.com/r/_ylt=A0SO8xqa8aRSkgYAiupXNyoA;_ylu=X3oDMTExOWpkbnBwBHNlYwNzcgRwb3MDMQRjb2xvA2dxMQR2dGlkA1VJQzFfMQ--/SIG=134t4tqr9/EXP=1386570266/**http%3a//www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/B/latex-table.pdf
Akehurst, C. (1998). Eurosurveillance, Volume 2, Issue 41, 08 October 1998. Eurosurveillance. Retrieved from http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=1143
Bernardo, J. (2012). Aluminum Toxicity. Medscape. Retrieved from http://emedicine.medscape.com/article/165315-overview#a0104
Blake, D. (1989). SmithKline Beecham to announce FDA approval for hepatitis vaccine. AP News Archive. Retrieved from http://www.apnewsarchive.com/1989/SmithKline-Beecham-To-Announce-FDA-Approval-For-Hepatitis-Vaccine/id-e0641fc20b8191c265b110baa04d3f2a
Blaylock, R. (2012). Aluminum induced immunoexcitotoxicity in neurodevelopmental and neurodegenerative disorders. Current Inorganic Chemistry. Retrieved from http://search.yahoo.com/r/_ylt=A0SO8oZHF6VSXC8A.SBXNyoA;_ylu=X3oDMTExM2o3NTViBHNlYwNzcgRwb3MDMwRjb2xvA2dxMQR2dGlkA1VJQzFfMQ--/SIG=12mhhm7vs/EXP=1386579911/**http%3a//www.geoengineeringwatch.org/documents/Aluminum-Blaylock.pdf
Brightman et al. (1989). Yeast-derived hepatitis B vaccine and yeast sensitivity. Lancet. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/2564981?dopt=Citation
CDC. (2013). Statistics and Surveillance. Centers for Disease Control and Prevention. Retrieved from http://www.cdc.gov/hepatitis/Statistics/index.htm
Chen et al. (1994). The vaccine adverse event reporting system (VAERS). Vaccine. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/8036829
Classen, J. (2013). Prevalence of Autism is Positively Associated with the Incidence of Type 1 Diabetes, but Negatively Associated with the Incidence of Type 2 Diabetes, Implication for the Etiology of the Autism Epidemic. Open Access Scientific Reports. Retrieved from http://www.vaccines.net/autism.pdf
DiMiceli et al. (2006). Vaccination of yeast sensitive individuals: review of safety data in the US vaccine adverse event reporting system (VAERS). Vaccine. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/16154669
Erguven et al. (2009). Optic neuritis following hepatitis B vaccination in a 9-year-old girl. J Chin Med. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/19948437
FDA. (1989). Vaccines, blood & biologics. U.S. Food and Drug Administration. Retrieved from http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm110154.htm
FDA. (1996). Vaccines, blood & biologics. U.S. Food and Drug Administration. Retrieved from http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm109871.htm
FDA. (1999). Vaccines, blood & biologics. U.S. Food and Drug Administration. Retrieved from http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm110129.htm
FDA. (2001). Vaccines, blood & biologics. U.S. Food and Drug Administration. Retrieved from http://www.fda.gov/biologicsbloodvaccines/vaccines/approvedproducts/ucm110085.htm
FDA. (2007). Vaccines, blood & biologics. U.S. Food and Drug Administration. Retrieved from http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm110142.htm
Gallagher et al. (2010). Hepatitis B vaccination of male neonates and autism diagnosis, NHIS 1997-2002. J Toxicol Environ Health. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/21058170
Gherardi et al. (2001). Macrophagic myofasciitis leasions assess long-term presistence of vaccine-derived aluminium hydroxide in muscle. Brain a Journal of Neurology. Retrieved from http://brain.oxfordjournals.org/content/124/9/1821.abstract
Girard, M. (2005). Autoimmune hazards of hepatitis B vaccine. Autoimmun Rev. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/15722255
GlaxoSmithKline. (1989). ENGERIX-B product insert. Retrieved from http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM224503.pdf
Haber et al. (2013). Intussusception after rotavirus vaccines reported to US VAERS, 2006-2012. Pediatrics. Retrieved from http://pediatrics.aappublications.org/content/early/2013/05/08/peds.2012-2554.abstract
Hamza et al. (2012). In vivo study of hepatitis B vaccine effects on inflammation and metabolism gene expression. Mol Biol Rep. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/21691704
Hernan et al. (2004). Recombinant hepatitis B vaccine and the risk of multiple sclerosis. Neurology. Retrieved from http://www.neurology.org/content/63/5/838.abstract
HRSA. (n.d.). Vaccine injury table. Health Resources and Services Administration. Retrieved from http://www.hrsa.gov/vaccinecompensation/vaccinetable.html
Khan et al. (2013). Slow CCL2-dependent translocation of biopersistent particles from muscle to brain. BMC Medicine. Retrieved from http://www.biomedcentral.com/1741-7015/11/99
Kidd, P. (1997). Glutathione: Systemic protectant against oxidative and free radical damage. Alternative Medicine Review. Retrieved from http://www.gotdownsyndrome.net/GSH.pdf
LGM Pharma blog. (2012). Entecavir versus a staggering number of hepatitis B cases worldwide. Retrieved from http://www.lgmpharma.com/blog/entecavir-versus-a-staggering-number-of-hepatitis-b-cases-worldwide/
McQuillan et al. (1999). Prevalence of hepatitis B virus infection in the United States: the National Health and Nutrition Examination surveys, 1976 through 1994. Am J Public Health. Retrieved from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1508496/?b
MedAlerts. (2013). Search the VAERS Database. Retrieved from http://www.medalerts.org/vaersdb/index.php
Merck. (1996). Comvax product insert. Retrieved from http://www.fda.gov/biologicsbloodvaccines/vaccines/approvedproducts/ucm174757.htm
Merck. (1999). Recombivax HB product insert. Retrieved from http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM110114.pdf
Mikaeloff et al. (2009). hepatitis B vaccine and the risk of CNS inflammatory demyelination in childhood. Neurology. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/18843097
NVIC. (1999). Hepatitis B vaccine reaction reports outnumber reported disease cases in children according to vaccine safety group. National Vaccine Information Center. Retrieved from http://www.nvic.org/nvic-archives/pressrelease/pressreleasejan271999.aspx
National Cancer Institute. (2011). Formaldehyde and Cancer Risk. National Institutes of Health. Retrieved from http://www.cancer.gov/cancertopics/factsheet/Risk/formaldehyde
Pande et al. (2013). Hepatitis B vaccination with or without hepatitis B immunoglobulin at birth to babies born of HBsAg-positive mothers prevents overt HBV transmission but may not prevent occult HBV infection in babies: a randomized controlled trial. GreenMedInfo. Retrieved from http://www.greenmedinfo.com/article/hepatitis-b-vaccination-or-without-hepatitis-b-immunoglobulin-birth-babies
Ratajczak, H. (2011). Theoretical aspects of autism: causes – a review. J Immunotoxicol. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/21299355
Rinaldi et al. (2013). Anti-saccharomyces cerevisiae autoantibodies in autoimmune diseases: from bread baking to autoimmunity. Clin Rev Allergy Immunol. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/23292495
Rosenthal et al. (1995). The reporting sensitivites of two passive surveillance systems for vaccine adverse events. Am J Public Health. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/7503351?dopt=Abstract
Seneff et al. (2012). Empirical data confirm autism symptoms related to aluminum and acetaminophen exposure. Entropy. Retrieved from http://www.mdpi.com/1099-4300/14/11/2227/pdf
Tomljenovic et al (2012). Mechanisms of aluminum adjuvant toxicity and autoimmunity in pediatric populations. Lupus. Retrieved from http://vaccinesafetycouncilminnesota.org/wp-content/uploads/2012/01/Mechanisms-of-aluminum-adjuvant-toxicity-and-autoimmunity-in-pediatric-populations.pdf
Tomljenovic et al. (2011). Aluminum Vaccine Adjuvants: Are they safe? Current Medicinal Chemistry. Retrieved from http://www.meerwetenoverfreek.nl/images/stories/Tomljenovic_Shaw-CMC-published.pdf
Tomljenovic et al (2011). Do aluminum vaccine adjuvants contribute to the rising prevalence of autism? J Inorg Biochem. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/22099159
Weisskopf, M., Morozova, N., O’Reilly E., McCullough, M., Calle, E., Thun, M., Ascherio, A. (2009). Prospective study of chemical exposures and amyotrophic lateral sclerosis. J Neruol Neurosurg Psychiatry. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/19372290
White, P. (1999). School nurses speak out on hepatitis B vaccine. International medical Council on Vaccination. Retrieved from http://www.vaccinationcouncil.org/2009/05/21/school-nurses-speak-out-on-hepatitis-b-vaccine/
Wu et al. (2013). Role of transient receptor potential ion channels and evoked levels of neuropeptides in a formaldehyde-induced model of asthma in BALB/c mice. PLoS One. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/23671638
Youth for Truth. (n.d.). STD’s Youth for Truth U.S.A. Retrieved from http://youthtruthusa.com/stds/
Yuan et al. (2012). Aluminum overload increase oxidative stress in four functional brain areas of neonatal rats. Journal of Biomedical Science. Retrieved from http://www.jbiomedsci.com/content/19/1/51
Zafrir et al. (2012). Autoimmunity following hepatitis B vaccine as part of the spectrum of ‘Autoimmune (Auto-inflammatory) Syndrome induced by adjuvants’ (ASIA): analysis of 93 cases. Lupus. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/22235045